Last updated: June 1, 2026
GLYBURIDE and METFORMIN HYDROCHLORIDE combination and stand-alone supply chains typically map to (1) finished-dose manufacturers that buy APIs and (2) API and intermediate suppliers that produce either the APIs directly or the key chemical intermediates that are converted into API under controlled quality systems. Specific supplier lists vary by dosage form and whether the product is sold as fixed-dose combination versus separate tablets, and by regulatory context (US ANDA versus other markets).
Below is a structured view of supplier categories and the most common source types for each API, and how procurement teams typically qualify and contract them.
Which companies supply metformin hydrochloride API for tablets?
Metformin hydrochloride API is supplied globally by large-scale API producers and by plants that specialize in fermentation and chemical conversion. The metformin API supply chain is mature, with multiple qualified manufacturers for both generic and branded markets.
Typical API supplier archetypes
- Tier-1 bulk API manufacturers: multi-product chemical plants with validated crystallization and drying for the API.
- Integrated intermediate-to-API producers: make key precursors and convert them to metformin hydrochloride under GMP.
- Contract manufacturers for solid oral dose: source metformin API and formulate tablets under CDMO scopes (API sourcing often remains with the API supplier or a centralized procurement group).
Key procurement documents procurement teams ask for (metformin)
- GMP manufacturing site information for metformin hydrochloride API
- CoA with impurity profile aligned to the target pharmacopeia specification
- DMF/ASMF linkages used for ANDA support (where applicable)
- Change control history for polymorph/crystal form and drying steps (metformin is sensitive to handling, though less so than some APIs)
What intermediate supply looks like for metformin
Metformin is generally produced via chemical synthesis routes using chlorinated or nitrogen-containing precursors (industry standard pathways differ by supplier). Procurement usually focuses less on naming intermediates and more on: (1) impurity controls, (2) route consistency, (3) crystallization parameters, and (4) ability to meet end-product impurity limits.
Which companies supply glyburide API for tablets?
Glyburide supply is more concentrated than metformin in many markets because glyburide has narrower commercial volumes and more complex synthesis steps than metformin. API sourcing often involves specialized API producers and intermediate specialists that can meet impurity and residual solvent targets.
Typical API supplier archetypes
- Specialty sulfonylurea API manufacturers: focus on glyburide and related sulfonylureas.
- Intermediate-to-API conversion suppliers: produce a key scaffold intermediate and then complete final conversion to glyburide.
- Sterile vs non-sterile: glyburide is oral solid; qualifying requirements center on solid-state properties, impurities, and milling/granulation behavior downstream.
Procurement focus areas for glyburide
- Batch-to-batch impurity profile (glyburide-specific impurities and process-related impurities)
- Control of residual solvents from recrystallization
- Compatibility with tablet formulation (particle size and flow properties for direct compression or granulation processes)
- DMF/ASMF support for ANDA filings and change management for route updates
Do suppliers differ for the fixed-dose combo product versus separate metformin and glyburide tablets?
Yes. Fixed-dose combination products (if marketed in a given country) often require that suppliers align on:
- API grades and impurity profiles
- Tablet excipient compatibility
- Controlled particle size distributions for both APIs in the same tablet matrix
- Formulation-specific acceptable variations under registered product specifications
When the product is marketed as separate tablets, procurement can use different supplier chains for each API and still meet end-product specs through formulation control and blend uniformity testing.
How many qualified suppliers exist for metformin hydrochloride versus glyburide?
Metformin hydrochloride typically has a larger universe of qualified suppliers globally due to higher volume usage across generic diabetes treatment portfolios. Glyburide tends to have fewer qualified suppliers relative to metformin, with more reliance on specialized sulfonylurea producers.
For procurement planning, the practical supplier count is determined by:
- How many suppliers have GMP history and impurity control at the level needed for your target regulatory dossier
- Whether suppliers can support your filing strategy via DMF/ASMF referencing
- Whether the end-product manufacturer is willing to qualify new API sources within the desired timeline
What is the typical contract manufacturing and API sourcing model for these drugs?
A common model for generic oral solids is:
- API supplier produces metformin hydrochloride and glyburide under GMP for DMF/ASMF or customer-specific specs.
- Formulation CDMO buys API and runs tablet manufacturing (blending, granulation, compression, coating if needed).
- ANDA sponsor/brand manufacturer runs stability programs and manages regulatory submissions.
If your goal is a fixed-dose combo tablet, the formulation step becomes tighter because both APIs must be co-processed into one blend with consistent uniformity and dissolution.
Which supplier quality systems matter most for GLYBURIDE and METFORMIN HYDROCHLORIDE?
For both drugs, qualification typically emphasizes:
- GMP compliance at the API site
- Documented impurity control and analytical validation
- Stability-indicating assays for API
- Traceability and batch genealogy
- Change control and notification terms in the master supply agreement
Because glyburide is more sensitive to impurity and particle property variation than metformin in many solid oral workflows, supplier quality audits often prioritize glyburide sites first when establishing new sourcing.
What regulatory-facing supplier documentation is used in the US?
In the US, ANDA and other regulatory submissions often rely on:
- DMFs/ASMFs for API drug substance manufacturing and controls
- Site correspondence and letter of authorization (where referenced)
- Specifications for impurities, residual solvents, polymorph/crystal form controls (as applicable), and stability
For metformin hydrochloride, the supplier universe is broad and documentation is often easier to source. For glyburide, the DMF/ASMF availability may be narrower, and active management of supplier documentation becomes more important in timelines.
Where do fixed-dose combo supply risks concentrate?
Risk concentrates in:
- API availability and batch timing: combo tablets require synchronized supply of both APIs to the same manufacturing window.
- Cross-API impurity specification interactions: dissolution and impurity limits can be impacted by both APIs’ particle properties and polymorph/crystal forms.
- Source change qualification: switching glyburide suppliers often triggers more end-product revalidation than switching metformin supplier, depending on existing comparability packages.
What do procurement teams look for in supplier selection criteria (practical checklist)?
Procurement typically ranks suppliers by:
- Ability to meet pharmacopoeia and customer impurity specs for metformin hydrochloride and glyburide
- GMP inspection history and quality metrics (deviations, CAPA closure times)
- Consistency of particle size distribution and crystal form (especially for glyburide)
- Capacity stability and lead times
- Willingness to support regulatory documentation and timely CoA release
- Contract terms for change notification, returns, and batch acceptance testing
Key Takeaways
- Metformin hydrochloride supply is broad and mature, with many qualified API sources.
- Glyburide supply is typically more specialized, with fewer qualified producers and tighter impurity and solid-state control expectations.
- Fixed-dose combo manufacturing increases procurement synchronization and qualification burden because both APIs must be controlled to one registered tablet specification.
- Supplier selection is driven by DMF/ASMF documentation readiness, impurity profiles, solid-state behavior, and quality-system maturity at the API site.
FAQs
- What are common DMF/ASMF considerations when sourcing metformin hydrochloride and glyburide for an ANDA?
- How do particle size and crystal form impact tablet uniformity and dissolution for glyburide and metformin hydrochloride?
- What supplier change-control triggers typically require bridging studies for fixed-dose combo tablets?
- Do residual solvent and impurity limits differ materially between metformin hydrochloride and glyburide suppliers?
- How do lead times and batch synchronization risks differ for fixed-dose combination versus separate tablets?
References
- United States Food and Drug Administration. “ANDA Submissions.” FDA.gov.
- European Medicines Agency. “Guideline on the Requirements for DMFs/ASMFs.” EMA guidance documents.
- U.S. Pharmacopeia (USP). Relevant monographs for metformin hydrochloride and glyburide, and general chapters on impurities and solid oral dosage forms.
